Cryogel-Based Dendritic Cell Immunotherapy for Post-Surgical Breast Cancer Treatment.

ABSTRACT: Triple-negative breast cancer (TNBC) is an aggressive malignancy with high mortality and limited treatment options. While surgical resection removes the primary tumor, it often fails to prevent recurrence or metastasis, and despite the promise of immunotherapy, response to immune checkpoint blockade remains poor. Here, a cryogel-based dendritic cell (DC) immunotherapy is developed incorporating gold nanodot-lipopolysaccharide (AuLPS)-loaded DCs, doxorubicin (Dox), and PD-1 immune checkpoint blockade (aPD-1+Dox+AuLPS@DC) to enhance post-surgical antitumor immunity. The AuLPS nanoparticles (NPs) stabilize LPS assembly, optimizing Th1 adjuvant activity and improving DC immunotherapy efficacy while minimizing adverse effects. The cryogel enables the sustained, localized release of therapeutic

SUBMITTER: Nguyen LD 

PROVIDER: S-EPMC12499431 | biostudies-literature | 2025 Oct

REPOSITORIES: biostudies-literature